U.S. drug overdose deaths have fallen to their lowest level in roughly a decade, according to new Centers for Disease Control and Prevention data. But researchers dispute a White House statement that attributed the decline primarily to policies enacted under President Donald Trump.
As reported on November 18, 2026, CDC data showed that overdose deaths began declining in 2023 and had continued to fall for at least 39 consecutive months. By the time former President Joe Biden left office, fatal overdoses had dropped by roughly one-third. The decline has continued under Trump.
The White House Office of National Drug Control Policy said the improvement had occurred primarily over the previous 18 months. Its director, Sara Carter, credited Trump’s border-security measures and efforts against drug-trafficking organizations. The office also described total overdose deaths as approximately 41.5% below their peak during the Biden administration.
Vanda Felbab-Brown, a drug policy expert at the Brookings Institution, said deaths had declined steadily since spring 2023. Nabarun Dasgupta, a researcher at the University of North Carolina at Chapel Hill, said some regions and demographic groups began seeing declines as early as 2021, while the fastest nationwide decline came from early 2024 through spring 2025.
Dasgupta, Felbab-Brown and other addiction experts credited Biden-era measures, including wider access to health care and the overdose-reversal medication naloxone, a U.S.-China agreement affecting shipments of chemicals used to make fentanyl, and efforts against Mexican cartels. They also said reductions in drug deaths have continued under Trump. Fentanyl remains the leading cause of U.S. drug deaths.
Asked about the earlier decline, Carter said Biden should not receive credit after overdose deaths reached record highs during his administration. She said the Trump administration could build on the reductions through border security and operations against drug-trafficking groups. Felbab-Brown disputed the administration’s claim of significant progress in dismantling those organizations, saying they continue to operate and smuggle drugs.
Researchers said establishing the timeline matters because the causes of both the fentanyl death surge and the subsequent decline remain under study. Dasgupta also raised concern about whether the decline can be sustained as Medicaid cuts enacted by the Republican-controlled Congress take effect. The Congressional Budget Office estimated that the cuts could leave as many as 10 million Americans without health insurance coverage.


